Akcea Therapeutics Inc (NASDAQ:AKCA) Shorted Shares Decreased By 3.5%

April 17, 2018 - By Winifred Garcia

The stock of Akcea Therapeutics Inc (NASDAQ:AKCA) registered a decrease of 3.5% in short interest. AKCA’s total short interest was 4.82M shares in April as published by FINRA. Its down 3.5% from 4.99 million shares, reported previously. With 476,600 shares average volume, it will take short sellers 10 days to cover their AKCA’s short positions. The short interest to Akcea Therapeutics Inc’s float is 32.49%.

The stock increased 7.29% or $1.63 during the last trading session, reaching $24. About 101,637 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.60 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Coverage

Among 2 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 3 analyst reports since October 31, 2017 according to SRatingsIntel. As per Tuesday, October 31, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained it with “Buy” rating and $20.0 target in Tuesday, November 7 report.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.